TAYLORE KUSEL: Open Payments
NPI 1598437097 · OWASSO, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$433 in 24 payments from 6 companies in 2025. Trend: 2023 $495 · 2024 $551 · 2025 $433
Food & beverage: $433
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 13 | $207 |
| Astellas Pharma US Inc | 2 | $60 |
| ABBVIE INC. | 3 | $56 |
| Sumitomo Pharma America, Inc. | 3 | $53 |
| PFIZER INC. | 2 | $34 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $24 |
Products named: Ozempic, Veozah, GEMTESA, UBRELVY, CAPLYTA, QULIPTA, PREVNAR 20, Wegovy.
Industry payments across OK — which companies pay providers there.
